Since MM presents a significant clinical challenge due to its aggressive nature and limited treatment options, immunotherapy has emerged as a promising strategy for MM, with a particular focus on immune checkpoint inhibitors such as PD-1 and CTLA-4 inhibitors [160,162]. Here, CTLA4 is linked to Miyoshi myopathy.